Study Shows CBD Could be Used to Help Treat Cannabis Addiction

The researchers claim that CBD may be able to address the "substantial and currently unmet clinical need" for a pharmacological method to treat cannabis addiction.

Researchers from the UK have published results from the world's first randomised clinical trial investigating the use of CBD to treat cannabis use disorders.

And data from the MRC-funded trial—which was published in Lancet Psychiatry—suggests that the non-intoxicating molecule could be used to help patients free themselves from addiction.

Our findings indicate that CBD doses ranging from 400mg to 800mg daily have the potential to reduce cannabis use in clinical settings, but higher doses are unlikely to bring any additional benefit. Larger studies are needed to determine the magnitude of the benefits of daily CBD for reducing cannabis use. University College London Director of Clinical Psychopharmacology, Professor Valerie Curran

The study measured the effect of CBD on the level of drug use over a four-week period, while also conducting additional follow-up data up to six months later.   

As part of the trial the researchers also elected to asses three different doses of the CBD to determine the optimum dosage, which was administered to 82 volunteers who were trying to quit cannabis but had failed to do so in the past.

According to the University of Bath's Director of the Addiction and Mental Health and lead study author, Dr. Tom Freeman, "the results from our trial open up a novel therapeutic strategy for managing problematic cannabis use in clinical settings."

"As we highlight, CBD at daily oral doses of 400mg and 800mg has potential to address the substantial and currently unmet clinical need for a pharmacological treatment of cannabis use disorders.

"Whilst it may seem counterintuitive to treat problematic cannabis use with CBD—a constituent part of the cannabis plant—THC and CBD have contrasting effects on our own endogenous cannabinoid system. Unlike THC, CBD does not produce intoxicating or rewarding effects and it shows potential for a treating several other medical disorders," Freeman said.

Participants were initially given 200mg, 400mg and 800mg doses of CBD for the first half of the trial, before electing to discontinue the lowest dose due to preliminary data that indicated it was largely ineffective.

During the second stage the researchers recruited an additional 34 patients to take part in the study, before eventually concluding that 400mg or 800mg doses were significantly more effective at reducing cannabis consumption when compared to a placebo.

This could prove to be a huge development for future cannabis addiction treatment methodology, as there is currently no recommended pharmacotherapy to assist people with problematic marijuana use.

However, even the authors of the study admit that larger scale studies are still required to determine the "magnitude of the benefits" that CBD can provide to those who are trying to quit cannabis.


This pot stock could reach new heights in 2020 due to Coronavirus

The COVID-19 pandemic is showing no signs of slowing down, and as global markets enter meltdown many cannabis companies are feeling the effects of capital crunch.

While the market crash will continue for some time, it represents a golden opportunity for investors who are capable of riding out the volatility until share prices rally.

Luckily, one pot stock has developed antimicrobial drug that can already treat two superbugs while limiting their ability to develop antibiotic resistance.

Investors can also start picking up shares at rock bottom prices, as global investor sentiment continues to dampen thanks to COVID-19.

Subscribe Now
& Keep Up to Date

Get the latest pot stock recommendations, cannabis news
and industry updates straight to your inbox!

Hugo Gray
Hugo Gray

Hugo Gray is a Melbourne-based journalist with a body of work that covers a diverse range of topics, including immigration law, sex technology, and now the rapidly expanding cannabis industry.

Leave a Reply

Your email address will not be published. Required fields are marked *